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Abstract
Introduction The molecular mechanisms involved in breast
cancer metastasis still remain unclear to date. In our previous
study, differential expression of peroxiredoxin 6 was found
between the highly metastatic MDA-MB-435HM cells and their
parental counterparts, MDA-MB-435 cells. In this study, we
investigated the effects of peroxiredoxin 6 on the proliferation
and metastatic potential of human breast cancer cells and their
potential mechanism.
Methods Expression of peroxiredoxin 6 in the highly metastatic
MDA-MB-231HM cells was investigated by RT-PCR, real-time
PCR and western blot. A recombinant expression plasmid of the
human peroxiredoxin 6 gene was constructed and transfected
into MDA-MB-231 and MDA-MB-435 cells. The effects of
peroxiredoxin 6 on the proliferation and invasion of MDA-MB-
231 and MDA-MB-435 cells were investigated by the Cell
Counting Kit-8 method, colony-formation assay, adhesion assay,
flow cytometry and invasion assay in vitro. miRNA was used to
downregulate the expression of peroxiredoxin 6. Genes related
to the invasion and metastasis of cancer were determined by
RT-PCR, real-time PCR and western blot. The tumorigenicity
and spontaneously metastatic capability regulated by
peroxiredoxin 6 were determined using an orthotopic xenograft
tumor model in athymic mice.
Results Overexpression of peroxiredoxin 6 in MDA-MB-231HM
cells compared with their parental counterparts was confirmed.
Upregulation of peroxiredoxin 6 enhanced the in vitro
proliferation and invasion of breast cancer cells. The
enhancement was associated with decreasing levels of tissue
inhibitor of matrix metalloproteinase (TIMP)-2 and increasing
levels of the urokinase-type plasminogen activator receptor
(uPAR), Ets-1 (E26 transformation-specific-1), matrix
metalloproteinase (MMP)-9 and RhoC (ras homolog gene
family, member C) expression. The results were further
demonstrated by RNA interference experiments in vitro. In an in
vivo  study, we also demonstrated that peroxiredoxin 6-
transfected breast cancer cells grew much faster and had more
pulmonary metastases than control cells. By contrast,
peroxiredoxin 6 knockdown breast cancer cells grew more
slowly and had fewer pulmonary metastases. Effects similar to
those of peroxiredoxin 6 on the uPAR, Ets-1, MMP-9, RhoC and
TIMP-2 expression observed in in vitro studies were found in the
in vivo study.
Conclusion Overexpression of peroxiredoxin 6 leads to a more
invasive phenotype and metastatic potential in human breast
cancer, at least in part, through regulation of the levels of uPAR,
Ets-1, MMP-9, RhoC and TIMP-2 expression.
BCA = bicinchoninic acid; bFGF = basic fibroblast growth factor; bp = base pair; BSA = bovone serum albumin; Ca2+ = calcium; CCK = Cell-Count-
ing Kit; CO2 = carbon dioxide; ECL = enhanced chemiluminescence; EDTA = ethylenediaminetetraacetic acid; Ets-1 = E26 transformation-specific-
1; EmGFP = enhanced Emerald Green Fluorescent Protein; FBS = fetal bovine serum; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; GSH 
= Glutathione; H&E = hematoxylin and eosin; HM = high metastasis; IGF = insulin-like growth factor; IGF-1R = IGF-1 receptor; MFP = mammary fat 
pad; miRNA, microRNA; MMP = matrix metalloproteinase; NIH = National Institutes of Health; OD = optical density; ORF = open-reading frame; PBS 
= phosphate-buffered saline; PCR = polymerase chain reaction; PRDX = peroxiredoxin; RhoC = ras homolog gene family, member C; ROS = reactive 
oxygen species; RNAi = RNA interference; RT-PCR = reverse-transcriptase PCR; Se = Selenium; TGF = transforming growth factor; TIMP = tissue 
inhibitor of MMP; TPM = tropomyosin; uPA = urokinase-type plasminogen activator; uPAR = uPA receptor; VEGF = vascular endothelial growth 
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Introduction
Breast cancer is the leading malignancy and also the leading
cause of death from cancer in women [1]. The vast majority of
these deaths are owing to metastasis. Although a number of
significant advances have been made, the molecular mecha-
nisms contributing to progression of breast cancer are poorly
understood.
In our previous study, a novel breast cancer cell line that was
derived from six cycles of pulmonary metastasis implantation
into the mammary fat pad (MFP), designated MDA-MB-
435HM (high metastasis (HM)), displayed significantly
enhanced pulmonary metastatic potential compared with its
parental counterparts, MDA-MB-435 cells [2]. Recently,
another novel, highly metastatic MDA-MB-231HM cell line,
derived from MDA-MB-231 cells, was also established and
maintained using the same methods. These cells provide
appropriate model systems, with a similar genetic background,
for the comparative study of the molecular events involved in
pulmonary metastasis of breast cancer.
In the postgenome era, global strategies are being developed
to identify new components of complex biological processes,
such as tumor cell metastasis. Proteomics enable the analysis
of thousands of modified or unmodified proteins simultane-
ously and has become increasingly popular for identifying
biomarkers for early detection, classification and prognosis of
tumors, in addition to pinpointing targets for improved treat-
ment outcomes. Our institute had used this approach to iden-
tify eleven proteins differentially expressed between the MDA-
MB-435HM cells and their parental counterparts, MDA-MB-
435 cells [2]. Some of these proteins, including peroxiredoxin
(PRDX) 6, were not described previously in breast cancer
metastasis. A significant association between PRDX6 staining
and the presence of lymph-node metastasis in 80 breast can-
cer donors was also observed. However, we do not know
whether PRDX6 is an instigator of metastasis or merely a cor-
relative product during progression of breast cancer.
PRDX6 is a bifunctional 25 kDa protein with both GSH (Glu-
tathione) peroxidase and phospholipase A2 activities. PRDX6
is expressed in many organs, with a particularly high level of
expression in the lungs; its peroxidase activity was first dem-
onstrated for protein isolated from the ciliary body of the
bovine eye [3]. Subsequently, a human cDNA that encodes
this protein was identified by random cloning [4]. The same
protein was subsequently isolated from rat lung as a calcium
(Ca2+)-independent phospholipase A2. Studies with recom-
binant proteins confirmed both Ca2+-independent phospholi-
pase A2 [5] and peroxidase activities [6].
PRDX6 is an important antioxidant enzyme and has a major
role in lung phospholipid metabolism. Manevich and Fisher
found that PRDX6 was stably overexpressed in cells protected
against oxidative stress, whereas antisense treatment resulted
in oxidant stress and apoptosis [7]. They postulated that
PRDX6 functions in antioxidant defense mainly by facilitated
repair of damaged cell membranes through reduction of per-
oxidized phospholipids. The phospholipase A2  activity of
PRDX6 is Ca2+-independent and maximal at acidic pH. Inhibi-
tion of phospholipase A2 activity results in alterations of lung-
surfactant phospholipid synthesis and turnover. However, the
role of PRDX6 in breast cancers remains unknown.
Materials and methods
Cell lines and animals
Human MDA-MB-435 and MDA-MB-231 breast cancer cell
lines were bought from ATCC (American Type Culture Collec-
tion, Manassas, VA, USA). The highly metastatic MDA-MB-
231HM cell line was established by our institute. Both MDA-
MB-435 and MDA-MB-231 cells were routinely maintained in
Leibovitz's L-15 medium with 2 mM of L-glutamine at 37°C in
a humidified atmosphere containing 5% carbon dioxide (CO2).
The medium was supplemented with 10% fetal bovine serum
(FBS), 100 U/ml of penicillin and 100 μg/ml of streptomycin.
The medium was changed every 2 to 3 days, and cells were
subcultured by treatment with 0.25% trypsin/0.53 mM EDTA
(ethylenediaminetetraacetic acid) solution. Female athymic
BALB/c-nu/nu mice, 4 to 6 weeks' old, were obtained from the
Shanghai Institute of Materia Medica of the Chinese Academy
of Sciences (Shanghai, China) and housed in laminar-flow
cabinets under specific pathogen-free conditions, with food
and water ad libitum. All experiments on mice were conducted
in accordance with the guidelines of National Institutes of
Health (NIH; Bethesda, MD, USA) for the care and use of lab-
oratory animals. The study protocol was also approved by
Shanghai Medical Experimental Animal Care Committee
(China).
RT-PCR and western blot analysis
Total RNA was extracted from cultured cells using TRIzol®
Reagent (Invitrogen, San Diego, CA, USA) and RT-PCR was
performed according to the manufacturer's instructions (MBI
Fermentas, Vilnius, Lithuania). Gene-specific primers for the
human PRDX6 gene (forward, 5'-TCATGGGGCATTCTCT-
TCTC-3'; reverse, 5'-TCTTCTTCAGGGATGGTTGG-3'; 497
bps) were synthesized at Shanghai Sangon Biological Engi-
neering & Technology Services Co. (Shanghai, China). PCR
products were separated on a 1.2% agarose gel and imaged
on an Alpha Image 950 documentation system (Alpha
Innotech, San Leandro, CA, USA). All experiments were
repeated at least three times, and the GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) gene (forward, 5'-
GGGAGCCAAAAGGGTCATCATCTC-3'; reverse, 5'-
CCATGCCAGTGAGCTTCCCGTTC-3'; 353 bps) was cho-
sen as an internal control.
To quantitatively determine the level of mRNA expression of
the PRDX6, cDNA templates of the cells were amplified by
real-time quantitative PCR. The reaction was performed usingAvailable online http://breast-cancer-research.com/content/9/6/R76
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the DNA Engine Opticon™ 2 real-time PCR detection system
(MJ Research, Watertown, MA, USA) with SYBR Green I
(Molecular Probes Inc, Eugene, OR, USA). GAPDH was cho-
sen as an internal control. The Opticon™ 2 apparatus was
used to measure the fluorescence of each sample in every
cycle at the end of the extension, and the comparative thresh-
old cycle (2-ΔΔcT) method was used to enable quantification of
the mRNA of these genes. All samples were run in triplicate.
After PCR, a melting curve was obtained and analyzed.
Western blot analysis was performed according to the previ-
ous method, with some modifications [8]. Briefly, proteins
were extracted from the cultured cells and then quantitated
using the bicinchoninic acid (BCA) assay kit (Pierce, Rock-
ford, IL, USA), with BSA as a standard. Equal amounts of pro-
tein (50 μg) from different cells were separated by 10% SDS-
PAGE and then incubated with mouse antihuman monoclonal
antibodies against PRDX6 (Chemicon International Inc.,
Temecula, CA, USA). Target proteins were detected by the
enhanced chemiluminescence (ECL) kit (Amersham Pharma-
cia Biotech, Uppsala, Sweden) and exposure to Biomax ML
film (Eastman Kodak, Rochester, NY, USA). Images were cap-
tured by Alpha Image 950 documentation system and ana-
lyzed by NIH Image version 1.62 (Alpha Innotech, San
Leandro, CA). The relative protein level in different cell lines
was normalized to the signal intensity of β-actin, as an internal
control.
Construction of a human peroxiredoxin 6 expression 
vector and stable transfections
A human PRDX6 expression vector was constructed using the
pcDNA™ 3.1 Directional TOPO® Expression Kit (Invitrogen),
according to the manufacturer's instructions. To construct the
human PRDX6 expression vector, the entire open-reading
frame (ORF) of the human PRDX6 gene (GenBank accession
no. D14662) was amplified from the recombinant plasmid vec-
tor pBlueScript II SK(+), in which the full-length KIAA0106
cDNA had been inserted (kindly provided by Professor Taka-
hiro Nagase, Kazusa DNA Research Institute, Chiba, Japan) by
PCR using high-fidelity Platinum® Taq DNA Polymerase (Invit-
rogen) and specific primers (upstream, 5'-CACCATGCCCG-
GAGGTCTGCTTCTC-3', with an added CACC underlined,
according to the manufacturer's instructions; downstream, 5'-
TTAAGGCTGGGGTGTGTAGCGGA-3'). The resulting con-
struct was named 'pcDNA3.1D/PRDX6'. After identification
by automated sequencing analysis, the recombinant DNA
plasmids transfected breast cancer cells using Lipo-
fectamine™ 2000 Transfection Reagent (Invitrogen), accord-
ing to the manufacturer's instructions. The positive colonies
were selected in the presence of 800 μg/ml of Geneticin®
(Invitrogen) and identified by RT-PCR and western blot analy-
sis. In this study, the clones in which the PRDX6 gene were
successfully transfected were named 'MDA-MB-435/PRDX6'
and 'MDA-MB-231/PRDX6', respectively. The cells only trans-
fected with the pcDNA3.1 vector were named 'MDA-MB-435/
vector' and 'MDA-MB-231/vector'. The transfectants were
used before passage 20 in all cases, to minimize the impacts
of clonal diversification and phenotypic instability. For all func-
tional and biological assays, cells between 70% and 90%
confluence were used, with viability > 95%.
Cell-proliferation assay
Cell-proliferation assays were performed to analyze the prolif-
eration potential of parental, empty vector and PRDX6-trans-
fected cells by using Cell-Counting Kit (CCK)-8 (Dojindo,
Kumamoto, Japan). The cells were harvested and plated in 96-
well plates at 1 × 103 cells/well and maintained at 37°C in a
humidified incubator. At the indicated time points, 10 μl of the
CCK-8 solution was added into the triplicate wells and incu-
bated for 1.5 hours and the absorbance at 450 nm was meas-
ured to calculate the numbers of vital cells in each well.
Colony-formation assay
The colony-formation assay was performed to measure growth
promotion by PRDX6 transfection, according to the previously
reported protocol [9], with some modifications. Identical num-
bers of parental cells, empty vector and PRDX6-transfected
cells were seeded in six-well tissue-culture plates to form col-
onies. After 10 days' incubation, the number of colonies (≥20
cells) was counted within a field at a magnification of × 200
under a light microscope. For each test, a total of five fields
were selected at random and the numbers were averaged. The
assay was repeated in at least three independent experiments,
with 0.5 × 104, 1 × 104 and 2 × 104 of the cells seeded,
respectively.
Flow cytometry
The parental, empty vector and PRDX6-transfected cells at
logarithmic growth phase were harvested and single-cell sus-
pensions containing 1 × 106 cells were made. The target cells
were treated following the standardized protocol and cell-
cycle analyses were performed by flow cytometry.
Adhesion assay
Matrigel™ (2 μg; BD Biosciences, San Jose, CA, USA) in 10
μl of serum-free culture medium was added to coat each well
of a 96-well culture plate and then 20 μl of medium containing
3% BSA was added to each well. The wells were incubated at
37°C for 1 hour and washed twice with warm PBS. A 100 μl
cell suspension that contained 5 × 104 cells was added to
each well. After incubation for 1 hour, the wells were washed
twice with PBS. We used the wells that were seeded with cor-
responding cells 6 hours previously as the control. The CCK-
8 was used to detect the optical density (OD) value of each
well. The adhesive rate was calculated according to the follow-
ing formula: rate = (the trial OD ÷ the control OD) × 100%.
In vitro invasion assays
In vitro invasion assays were performed to analyze the invasive
potential of parental, vector and PRDX6-transfected cellsBreast Cancer Research    Vol 9 No 6    Chang et al.
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using a Matrigel™ invasion chamber (Becton Dickinson
Labware, Bedford, MA, USA), as described previously, with
some modifications [10]. Each well insert was coated with
100 μl of a 1:3 dilution of Matrigel™ in serum-free culture
medium. Then, a mixture of 200 μl of medium with 10% FBS,
200 μl of the supernatant of the corresponding cell culture and
200 μl of the supernatant of the NIH/3T3 cell culture was
added to the lower chambers as a chemoattractant, and 1 ×
105 cells in 250 μl of serum-free medium were added to the
top of this Matrigel™ layer. The cells were incubated at 37°C
for 24 hours. The cell suspension was aspirated and excess
Matrigel™ was removed from the filter using a cotton swab.
Then, the filters were fixed in 10% formalin solution and
stained with H & E. Cells that had invaded through the
Matrigel™ and reached the lower surface of the filter were
counted under a light microscope at a magnification of × 200.
Five fields should be counted for each sample.
RNA interference experiments
To further demonstrate the role for PRDX6 in the progression
of human breast cancer, we used the RNA interference (RNAi)
technique to downregulate PRDX6 expression using the
BLOCK-iT™ Pol II miR RNAi Expression Vector Kit (Invitrogen),
according to the manufacturer's instructions.
The pcDNA™6.2-GW/EmGFP-miR plasmid with a spectino-
mycin-resistance gene (Invitrogen, San Diego, CA, USA) was
used for cloning small synthetic oligonucleotides. Four differ-
ent miR155-based PRDX6-targeting sequences were
designed using Invitrogen's RNAi design algorithm online.
These sequences are shown in Table 1. On the basis of the
computer analysis, these inserted oligonucleotides would spe-
cifically bind homologous sites of PRDX6 mRNA and thus
might interfere with PRDX6 expression in cultured cells. To
identify successful construction of recombinant plasmids, the
EmGFP (enhanced Emerald Green Fluorescent Protein) for-
ward-sequencing primer (5'-GGCATGGACGAGCTGTA-
CAA-3') and miRNA reverse-sequencing primer (5'-
CTCTAGATCAACCACTTTGT-3') were designed to perform
PCR. After PCR, the plasmids that contained the miRNA insert
fragments were verified by DNA sequencing. Finally, the
mutants were excluded from this experiment and the right one
was purified using QIAGEN Plasmid Maxi (tip 500) Kit (QIA-
GEN, Hilden, Germany).
Transfection of miRNA plasmids
The pcDNA™6.2-GW/EmGFP-miR expression vectors (Invit-
rogen, San Diego, CA, USA) containing either the PRDX6
miRNA insert (pCMV-PRDX6 miRNA-122, pCMV-PRDX6
miRNA-251, pCMV-PRDX6 miRNA-289 or pCMV-PRDX6
miRNA-672) or the pcDNA™6.2-GW/EmGFP-miR-neg con-
trol plasmid (Invitrogen) were transfected into target cells with
the Lipofectamine 2000 reagent, according to the manufac-
turer's instructions. After 48 hours of transfection, RT-PCR,
real-time PCR and western blot analysis were performed to
assess the selectivity of PRDX6 knockdown. Successfully
transfected cells clones were obtained by long-term culture in
a selection medium containing 4 μg/ml of blasticidin. After 3
months, RT-PCR, real-time PCR and western blot analysis
were performed to confirm the knockdown of PRDX6.
In vitro invasion assay
The effects of reduced PRDX6 expression on the invasion
capacity of breast cancer cells were determined by in vitro
invasion assay, as described previously. All experiments were
performed in triplicate.
RT-PCR and western blot analysis
The levels of mRNA and protein expression of matrix metallo-
proteinase (MMP)-1, MMP-2, MMP-7, MMP-9, transcriptional
factor Ets-1 (E26 transformation-specific-1), tissue inhibitor of
MMP (TIMP)-1, TIMP-2, urokinase-type plasminogen activator
(uPA), the uPA receptor (uPAR), cathepsin D, maspin, cystatin
C, vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), RhoC (ras homolog gene family, mem-
ber C), P21, IGF(insulin-like growth factor)-1, IGF-1R (IGF-1
Table 1
The oligonucleotide sequences of shRNA (short hairpin RNA) driven by CMV(Cytomegalovirus) promoter in pcDNA™6.2-GW/
EmGFP-miR (peroxiredoxin 6; GenBank accession no. D14662) (Invitrogen, San Diego, CA, USA)
Top oligo Bottom oligo
pCMV-PRDX6miRNA-122
(122–142 nt)
TGCTGCCATGAGTCTCCCAGAAAGTCGTTTTGGC
CACTGACTGACGACTTTCTGAGACTCATGG
CCTGCCATGAGTCTCAGAAAGTCGTCAGTCAGTG
GCCAAAACGACTTTCTGGGAGACTCATGGC
pCMV-PRDX6miRNA-251
(251–271 nt)
TGCTGAACACTGTCTATTGAAAGGGCGTTTTGGCC
ACTGACTGACGCCCTTTCTAGACAGTGTT
CCTGAACACTGTCTAGAAAGGGCGTCAGTCAGTG
GCCAAAACGCCCTTTCAATAGACAGTGTTC
pCMV-PRDX6miRNA-289
(289–309 nt)
TGCTGTAAGCATTGATATCCTTGCTCGTTTTGGCCA
CTGACTGACGAGCAAGGATCAATGCTTA
CCTGTAAGCATTGATCCTTGCTCGTCAGTCAGTGG
CCAAAACGAGCAAGGATATCAATGCTTAC
pCMV-PRDX6miRNA-672
(672–692 nt)
TGCTGATTTCTTGCCAGATGGGAGCTGTTTTGGCC
ACTGACTGACAGCTCCCATGGCAAGAAAT
CCTGATTTCTTGCCATGGGAGCTGTCAGTCAGTGG
CCAAAACAGCTCCCATCTGGCAAGAAATCAvailable online http://breast-cancer-research.com/content/9/6/R76
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receptor), IGF-2, cyclin A, cyclin D1, cyclin E, E-cadherin, ps2,
C-jun, C-fos, trophinin, tropomyosin (TPM)4 and TGF(trans-
forming growth factor)-α in the control cells, PRDX6 transfect-
ants and PRDX6-knockdown cells were determined by RT-
PCR, real-time PCR and western blot analysis, respectively.
The primers were designed using Primer 3 software
(Whitehead Institute for Biomedical Research, Cambridge,
MA, USA) (Additional file 1). All experiments were performed
in triplicate.
Tumorigenicity and metastasis assays in athymic mice
The tumorigenicity and spontaneously metastatic capability of
the different cells were determined using an orthotopic
xenograft tumor model in the athymic mice, as described pre-
viously [11]. Animals were divided into four groups: the paren-
tal, empty vector, PRDX6-transfected and pCMV-PRDX6
miRNA-672 (PRDX6 knockdown) groups. Each group had
eight mice. MDA-MB-435 or MDA-MB-231 cells (5 × 106 or 2
× 106 cells, respectively) were injected orthotopically into the
exposed axillary MFP of anesthetized athymic mice. The cells
in PRDX6 knockdown groups were inoculated 4 weeks after
transfection. Animals were monitored every 2 days for tumor
growth and general health. The rate of primary tumor growth of
different cells was determined by plotting the means of two
orthogonal diameters of the tumors, measured at 7-day inter-
vals. Animals were killed and autopsied at 8 weeks for MDA-
MB-435 cells or 6 weeks for MDA-MB-231 cells postinocula-
tion. The lungs used to evaluate the numbers of metastasis
were fixed in Bouin's solution for 24 hours and then stored in
100% ethanol. When the lungs restored their inherent color,
the white metastasis deposits could be assessed by macro-
scopic observation. To confirm the presence of lung metas-
tases, sections were cut at 50 μm intervals and H & E staining
was performed. In this study, the number of metastasis nod-
ules on the lung surface was counted. Two independent
pathologists calculated the number of metastases. Tissue
samples harvested for western blot analysis were snap-frozen
in liquid nitrogen.
Western blot analysis of PRDX6, uPAR, Ets-1, MMP-9, 
RhoC and TIMP-2 expression in xenograft tumor tissues 
Proteins were extracted from the above frozen tissues and
quantitated with the BCA assay kit. Western blot analysis was
performed according to the methods described above. The
relative protein expression of PRDX6, the uPAR, Ets-1, MMP-
9, RhoC and TIMP-2 in xenograft tumor tissues of different
groups was normalized to the signal intensity of β-actin.
Statistical analysis
Statistical analysis was performed using the software of Sta-
tistical Package for the Social Sciences (SPSS) Version 11.5
for Windows (SPSS Inc., Chicago, IL, USA) and P < 0.05 was
considered as statistically significant.
Results
Expression of peroxiredoxin 6 in different MDA-MB-231 
cells
To confirm the roles of PRDX6 in MDA-MB-231 cells, RT-
PCR, real-time PCR and western blot analysis of PRDX6 were
performed. As shown in Figure 1, results of replicate samples
from MDA-MB-231HM and MDA-MB-231 cells confirmed a
close correlation similar to that of MDA-MB-435 revealed by
proteomic analysis [2], which indicated the functional rele-
vance to breast cancer development and metastasis.
In vitro effect of peroxiredoxin 6 overexpression on 
breast cancer cells
Stable transfection and expression analysis
A human PRDX6 expression vector was constructed and con-
firmed by automated DNA sequencing. To investigate the
effects of PRDX6 on the metastatic phenotype of breast can-
cer cells, stable PRDX6 transfectants of MDA-MB-231 and
MDA-MB-435 cells were established. As shown in Figure 2,
RT-PCR, real-time PCR and western blot analysis revealed
higher levels of PRDX6 expression in the two PRDX6 trans-
fectants (MDA-MB-231/PRDX6-1 and MDA-MB-435/
PRDX6-1) compared with the parental, vector control or other
transfectant cells, respectively. In this study, both clones were
selected as MDA-MB-231/PRDX6 and MDA-MB-435/
PRDX6 for the subsequent experiments.
Cell-proliferation assay
We assessed the growth of the parental, PRDX6-transfected
and vector-transfected cells. As shown in Figure 3a,b, PRDX6
was able to increase the proliferation of MDA-MB-231 and
MDA-MB-435 cells significantly at day 3, 4 and 5 (P < 0.05).
Colony-formation assay
In all three groups, PRDX6-transfected cells formed more col-
onies than the control, but a statistically significant difference
was only observed in the group of 1 × 104 cells (P < 0.05; Fig-
ure 3c,d).
Flow cytometry
Analysis of the cell cycle by flow cytometry also showed that
the percentage of S-phase PRDX6-transfected cells was
higher than that of the control cells (P < 0.05; Figure 3e,f).
Adhesion assay
The cell-adhesive ability was one of the key determinants of
tumor metastasis. We examined the potential of different cells
to adhere to Matrigel™ using the CCK-8 assay. As shown in
Figure 3g,h, the values of transfected cells were higher than
those of the control (P < 0.05).
In vitro invasion assays
In vitro invasion assays were performed to determine the
effect of PRDX6 on cell invasion using the Boyden chamber
assay (BD Biosciences Discovery Labware, Bedford, MA,Breast Cancer Research    Vol 9 No 6    Chang et al.
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USA). The Matrigel™ matrix served as a reconstituted base-
ment membrane in vitro. The number of cells migrating through
the Matrigel™ matrix was counted and the result is presented
in Figure 3i,j. The PRDX6 transfectants showed higher inva-
sive capacity than either parental or empty vector cells (P <
0.05).
RNA interference experiments
miRNA constructs inhibited peroxiredoxin 6 expression
After PCR and DNA sequencing, the four recombinant plas-
mids targeting PRDX6 (pCMV-PRDX6 miRNA-122, pCMV-
PRDX6 miRNA-251, pCMV-PRDX6 miRNA-289 and pCMV-
PRDX6 miRNA-672) were transfected into the MDA-MB-231
and MDA-MB-435 cells, respectively. To evaluate inhibition of
PRDX6, RT-PCR, real-time PCR and western blot analysis
were performed to compare the expression levels of PRDX6
among the parental, pCMV-PRDX6 miRNA-122-transfected,
pCMV-PRDX6 miRNA-251-transfected, pCMV-PRDX6
miRNA-289-transfected, pCMV-PRDX6 miRNA-672-trans-
fected and pCMV-PRDX6 miRNA-neg-transfected cells 48
hours after transfection. As shown in Figure 4, PRDX6 was
strongly inhibited in pCMV-PRDX6 miRNA-672-transfected
cells.
To assess the phenotype of tumor cells in which PRDX6
expression was inhibited over a long-term period, we gener-
ated stable PRDX6-downregulated clonal cell lines. One of
clones from pCMV-PRDX6 miRNA-672-transfected cells was
chosen and cultured for a long-term period in a selection
medium containing blasticidin. At 3 months, RT-PCR, realtime
PCR and western blot analysis of the clone cells demon-
strated decreased PRDX6 expression compared with parental
cells (P < 0.05; Additional file 2).
Peroxiredoxin 6 knockdown inhibited breast cancer cell 
invasion in vitro
pCMV-PRDX6 miRNA-672 was used to knockdown PRDX6
in MDA-MB-231 and MDA-MB-435 cells, to determine
whether PRDX6 expression was crucial to the invasive pheno-
type in vitro. As shown in Figure 5, reduced PRDX6 expres-
sion in both cell types significantly inhibited the invasive
capacity  in vitro compared with parental and nonsilencing
control cells (P < 0.05).
PRDX6 regulates uPAR, Ets-1, MMP-9, RhoC and TIMP-2
expression To further explore the molecular mechanisms
underlying the PRDX6-mediated invasion phenotype in vitro,
Figure 1
RT-PCR, real-time PCR and western blot analysis of PRDX6 differentially expressed in MDA-MB-231HM (lane 2) and parental MDA-MB-231 cells  (lane 1) RT-PCR, real-time PCR and western blot analysis of PRDX6 differentially expressed in MDA-MB-231HM (lane 2) and parental MDA-MB-231 cells 
(lane 1). Differential expression of PRDX6 in both cell lines revealed by RT-PCR (a) and quantitative real-time PCR (b) analysis. (c) Representative 
immunodetection of PRDX6 is shown. (d) Relative protein expression of PRDX6 in different cell lines was normalized to the signal intensity of β-
actin. PRDX, peroxiredoxin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Available online http://breast-cancer-research.com/content/9/6/R76
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Figure 2
Expression of PRDX6 in PRDX6 transfectants and control cells Expression of PRDX6 in PRDX6 transfectants and control cells. RT-PCR (a) and quantitative real-time PCR (b) analysis of PRDX6 expression in dif-
ferent MDA-MB-231 cells. Lanes 1 to 6: negative control (total RNA sample of MDA-MB-231HM cells without reverse transcription), MDA-MB-231, 
MDA-MB-231/vector, MDA-MB-231/PRDX6-1, MDA-MB-231/PRDX6-2 and MDA-MB-231/PRDX6-3.(c) Western blot analysis of PRDX6 expres-
sion in different MDA-MB-231 cells. Lanes 1 to 5: MDA-MB-231, MDA-MB-231/vector, MDA-MB-231/PRDX6-1, MDA-MB-231/PRDX6-2 and 
MDA-MB-231/PRDX6-3.(d) Relative protein expression of PRDX6 in different cell lines. RT-PCR (e) and quantitative real-time PCR (f) analysis of 
PRDX6 expression in different MDA-MB-435 cells. Lanes 1 to 6: negative control, MDA-MB-435, MDA-MB-435/vector, MDA-MB-435/PRDX6-1, 
MDA-MB-435/PRDX6-2 and MDA-MB-435/PRDX6-3. (g) Western blot analysis of PRDX6 expression in different MDA-MB-435 cells. Lanes 1 to 
5: MDA-MB-435, MDA-MB-435/vector, MDA-MB-435/PRDX6-1, MDA-MB-435/PRDX6-2 and MDA-MB-435/PRDX6-3. (h) Relative protein 
expression of PRDX6 in different cell lines. PRDX, peroxiredoxin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.Breast Cancer Research    Vol 9 No 6    Chang et al.
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Figure 3
In vitro effects of PRDX6 overexpression on MDA-MB-231 cells In vitro effects of PRDX6 overexpression on MDA-MB-231 cells. Growth curves for parent cells, empty vector and PRDX6-transfected cells in an in 
vitro proliferation assay for MDA-MB-231 (a) and MDA-MB-435 (b) cells. Colony-formation assay in the group of 1 × 104 cells for MDA-MB-231 (c) 
and MDA-MB-435 (d) cells. Representative results of flow-cytometric analysis for MDA-MB-231 (e) and MDA-MB-435 (f) cells. The percentage of 
PRDX6-transfected cells in the S-phase was higher than that in the two control cells. The cell-adhesive potential of different cells was compared for 
MDA-MB-231 (g) and MDA-MB-435 (h) cells. The potential of PRDX6-transfected cells for adhesion was higher than that of the two control cells. 
In vitro Matrigel™ invasion assay (BD Biosciences Discovery Labware, Bedford, MA, USA) for MDA-MB-231 (i) and MDA-MB-435 (j) cells. The 
PRDX6-transfected cells were more invasive than their parental counterparts (P < 0.05). OD, optical density; PRDX, peroxiredoxin.Available online http://breast-cancer-research.com/content/9/6/R76
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Figure 4
Transfection with pCMV-PRDX6 miRNA efficiently silences PRDX6 expression in breast cancer cells Transfection with pCMV-PRDX6 miRNA efficiently silences PRDX6 expression in breast cancer cells. Lanes 1 to 6: the parents, pCMV-PRDX6 
miRNA-122-transfected, pCMV-PRDX6 miRNA-251-transfected, pCMV-PRDX6 miRNA-289-transfected, pCMV-PRDX6 miRNA-672-transfected 
and pCMV-PRDX6 miRNA-neg-transfected cells. RT-PCR (a) and real-time PCR (b) illustrated that pCMV-PRDX6 miRNA-672, rather than pCMV-
PRDX6 miRNA-neg, pCMV-PRDX6 miRNA-122, pCMV-PRDX6 miRNA-251 or pCMV-PRDX6 miRNA-289, reduced PRDX6 mRNA in MDA-MB-
231 cells. (c) A representative western blot image illustrated that pCMV-PRDX6 miRNA-672, rather than the other miRNA groups, reduced PRDX6 
proteins in MDA-MB-231 cells.(d) The relative expression of PRDX6 protein in the different MDA-MB-231 cells above. RT-PCR (e) and real-time 
PCR (f) illustrated that pCMV-PRDX6 miRNA-672, rather than the other miRNA groups, reduced PRDX6 mRNA in MDA-MB-435 cells. (g) A repre-
sentative western blot image illustrated that pCMV-PRDX6 miRNA-672, rather than the other miRNA groups, reduced the levels of PRDX6 protein 
in MDA-MB-435 cells. (h) The relative expressions of PRDX6 protein in the different MDA-MB-435 cells above. PRDX, peroxiredoxin; GAPDH, glyc-
eraldehyde-3-phosphate dehydrogenase.Breast Cancer Research    Vol 9 No 6    Chang et al.
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we focused on the several recognized invasion-associated
genes. RT-PCR, real-time PCR and western blot analysis
showed that PRDX6 transfectants constitutively express high
levels of the uPAR, transcriptional factor Ets-1, MMP-9 and
RhoC and low levels of TIMP-2 compared with control vector-
transfected or parental cells. In the PRDX6 knockdown cells,
the uPAR, Ets-1, MMP-9 and RhoC were downregulated and
TIMP-2 was upregulated (Additional file 3). However, we did
not find any significant differences in MMP-1, MMP-2, MMP-7,
TIMP-1, uPA, cathepsin D, maspin, cystatin C, VEGF, bFGF,
P21, IGF-1, IGF-1R, IGF-2, cyclin A, cyclin D1, cyclin E, E-
cadherin, ps2, C-jun, C-fos, trophinin, TPM4 and TGF-α
expression among the parental, PRDX6 transfectants, PRDX6
knockdown and control vector cells (data not shown).
Tumor growth and pulmonary metastasis in the athymic 
mice were regulated by the expression of peroxiredoxin 
6
The effect of PRDX6 expression on tumor growth and metas-
tasis was further assayed in athymic mice. Results revealed
that PRDX6-transfected groups grew faster than either vector-
transfected or parental groups and PRDX6 knockdown
groups grew slower than the other three groups (Figure 6a,b).
To study pulmonary metastasis, at the experimental end point,
lungs were examined physically at autopsy and overt surface
metastases were observed. For MDA-MB-231 cells, surface
metastases were found in half of mice in the PRDX6-trans-
fected groups, 12.5% of the parental group and none of the
vector-transfected and PRDX6 knockdown groups. The differ-
ence between the PRDX6-transfected and the PRDX6 knock-
down groups was significant (P < 0.05). Because MDA-MB-
231 cells have a low potential for lung metastasis, we did not
find a significant difference in lung metastases between the
other groups. Furthermore, lungs were subjected to micro-
scopic examination for morphologic evidence of tumor cells on
H & E-stained paraffin sections. The most micrometastases
were observed in PRDX6-transfected mice. Only a few or no
micrometastases were observed in mice of parental, vector-
transfected or knockdown groups (Figure 6c). For MDA-MB-
435 cells, the most micrometastases were observed in the
lungs of the PRDX6-transfected group, whereas the PRDX6
knockdown mice had the fewest micrometastases (Figure 6d).
The number of overt surface metastases in the lungs of the
PRDX6-transfected group was largest and that of the PRDX6
knockdown group was smallest (Figure 6e). The difference
between the PRDX6-transfected or knockdown groups and
the parental group was significant (P  < 0.05). In addition,
effects similar to those of PRDX6 on uPAR, Ets-1, MMP-9,
RhoC and TIMP-2 expression observed in the in vitro studies
were also found in the in vivo studies (Figure 6f–g).
Discussion
Recently, many metastasis-related proteins have been found in
different kinds of tumors by using the proteomic approach. In
our institute, Li and colleagues have identified 11 proteins with
significantly different expression levels in the high–metastatic-
potential MDA-MB-435HM cells and their lower-metastatic-
potential parental counterpart by using a comparative pro-
teomic approach [2]. PRDX6 is one of the proteins with differ-
ent levels of expression.
PRDXs represent a superfamily of Se(selenium)-independent
peroxidases and some studies have showed a significant rela-
tionship between the expression of PRDXs and breast cancer.
Noh and colleagues [12] reported that PRDX1, PRDX2 and
PRDX3 were overexpressed in breast cancer tissues, sug-
gesting that PRDXs had a proliferative effect and might be
related to cancer development or progression. Karihtala and
colleagues [13] observed that staining for PRDX2 and PRDX6
was negative in half of breast cancer cases, whereas PRDX1,
PRDX3, PRDX4 and PRDX5 showed stronger expression lev-
els. They also found that expression of PRDX5 was signifi-
Figure 5
Downregulation of PRDX6 in breast cancer cells decreased the invasion capacity in vitro Downregulation of PRDX6 in breast cancer cells decreased the invasion capacity in vitro. In vitro invasion assays of the invasive potential of the dif-
ferent MDA-MB-231 (a) and MDA-MB-435 cells (b). PRDX, peroxiredoxin.Available online http://breast-cancer-research.com/content/9/6/R76
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Figure 6
Regulation of the growth and pulmonary metastasis of breast cancer cells by PRDX6 in in vivo studies Regulation of the growth and pulmonary metastasis of breast cancer cells by PRDX6 in in vivo studies. The growth curves for different MDA-MB-
231 (a) and MDA-MB-435 (b) cells in an in vivo proliferation assay. Photomicrographs of micrometastases (arrow) in lung sections obtained from 
mice bearing parental (a), vector-transfected (b), PRDX6-transfected (c) and PRDX6 knockdown (d) groups for MDA-MB-231 (c) and MDA-MB-
435 (d) cells (H & E; × 200). (e) Metastasis numbers per lung in parental, vector-transfected, PRDX6-transfected and PRDX6 knockdown groups at 
week 8 for MDA-MB-435 cells. The relative protein expression of PRDX6, uPAR, Ets-1, MMP-9, RhoC and TIMP-2 was normalized to the signal 
intensity of β-actin for MDA-MB-231 (f) and MDA-MB-435 (g) cells. MMP, matrix metalloproteinase; PRDX, peroxiredoxin; TIMP, tissue inhibitor of 
MMP; uPAR, urokinase-type plasminogen activator receptor; Ets-1, E26 transformation-specific-1; RhoC, ras homolog gene family member C.Breast Cancer Research    Vol 9 No 6    Chang et al.
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cantly stronger if tumors were larger or had lymph-node
metastases. Liu and colleagues [14] reported that in a MDR
(multidrug resistant) cell line MCF7/AdVp3000 the expression
of PRDX6 was increased and the expression of PRDX2 was
decreased, which suggested they might cause drug resist-
ance to chemotherapy in breast cancer. In addition, the over-
expression of PRDX2, resulting in increased resistance of
breast cancer cells to ionizing radiation [15], and involvement
of PRDX in breast cancer resistance to docetaxel therapy
were also observed [16].
The PRDX6 gene located at chromosome 1q2 consists of five
exons and encodes a 25 kDa protein. There have been numer-
ous reports documenting a link between PRDX6 and certain
diseases, such as atherosclerosis [17], sporadic Creutzfeldt–
Jacob disease [18] and Pick disease [19]. However, until now,
there was little information about the role of PRDX6 in the
metastasis of cancers, including breast cancer.
In the present study, we found that PRDX6 was upregulated
in MDA-MB-231HM cells. These results are consistent with
the previous results in MDA-MB-435HM cells, suggesting that
expression of PRDX6 takes part in the process of invasion and
metastasis of breast cancer. We also established the PRDX6-
overexpressing MDA-MB-231 and MDA-MB-435 cell lines by
stable transfection. Both transfected cell types exhibited the
significantly enhanced proliferative potential compared with
their parental cells. The results of adhesion and invasive
assays in vitro also showed that PRDX6 could promote the
invasion and migration of breast cancer cells. This provided
direct evidence that PRDX6 could enhance the invasive
potential of breast cancer.
At first glance, our results seem to contradict some of the pub-
lished literature regarding the relationship between PRDXs
and cancers. Ouyang and colleagues [20] found that progres-
sion of prostate adenocarcinoma was correlated to the dereg-
ulation of antioxidants, including PRDX6, in Nkx3.1 mutant
mice. They thought that the deregulation of antioxidants led to
an accumulation of reactive oxygen species (ROS) and, ulti-
mately, the initiation and progression of prostate carcinoma.
This result was verified in some other studies. Neumann and
colleagues [21] found that mice lacking PRDX1 have a short-
ened lifespan partly owing to several malignant cancers,
including breast cancer. de Souza and colleagues observed
decreases in the expression of PRDX2 and PRDX6 proteins
[22] in murine melanoma line Tm1 compared with Tm5 from
nontumor cells.
However, some other studies showed upregulation of PRDX6
in malignant tumors. Karihtala and colleagues [13] found that
PRDXs, including PRDX6, were overexpressed in breast can-
cer. Quan and colleagues [23] demonstrated that enhanced
PRDX6 expression was strongly associated with bladder can-
cer development. Furthermore, overexpression of PRDX6 was
found in malignant mesothelioma of the lung [24].
Why is there such disparity in the literature regarding PRDX6
expression in various studies? One possibility might be differ-
ences in cell types. Most of the reports about the downregula-
tion of PRDXs originated from studies in murine malignant
cells. Another possible explanation for increased PRDX levels
in tumors would be that they were the results of responding to
impending oxidative stress and that antiapoptotic features of
PRDXs provided a growth advantage to tumor cells [13]. It
was probable that PRDXs were able to inhibit ROS-mediated
physiological apoptosis, cause abnormal proliferation and
thereby lead to tumorigenesis. However, for the deregulation
of PRDXs in some malignant cells, a lack of PRDX led to an
accumulation of ROS, which promoted carcinogenesis in all
its stages, for example initiation, promotion and progression
[25]. Clearly, further studies should be done to explain these
contradictions.
In the present study, we also used miRNA-induced gene
silencing to further demonstrate the relationship between inva-
sive potential and expression of PRDX6. A miRNA expression
vector derived from a murine miR-155 sequence, which ena-
bles the expression of engineered miRNA sequences from Pol
II promoters, was used to construct a PRDX6-targeting
miRNA expression vector. Four different vectors, pCMV-
PRDX6 miRNA-122, pCMV-PRDX6 miRNA-251, pCMV-
PRDX6 miRNA-289 and pCMV-PRDX6 miRNA-672, were
constructed in this study. We found that the expression of
PRDX6 was significantly decreased in pCMV-PRDX6 miRNA-
672 groups of breast cancer cells. To confirm their stable
nature for future inoculation in vivo, we generated stable trans-
fectants of PRDX6 knockdown and the obvious inhibition was
observed at 3 months. We found that PRDX6 knockdown
cells exhibited marked inhibition in invasive potential and the
inhibition might be related to the regulation of uPAR, Ets-1,
MMP-9, RhoC and TIMP-2 levels.
A crucial step during invasion and metastasis is the destruc-
tion of biological barriers, such as the basement membrane,
which requires activation of proteolytic enzymes. Many studies
have shown that enhanced production of members of the plas-
minogen activator pathway and MMP family contributed to
tumor invasion, metastasis and angiogenesis [26]. The uPAR
could regulate cell-surface-associated proteolysis by uPA [27]
and it was also involved in the regulation of cell adhesion and
migration independent of the enzymatic activity of its ligand
[28]. In this study, we have demonstrated that upregulated
expression of the uPAR, but not uPA, was associated with
increased tumor cell invasion and metastasis in breast cancer
by PRDX6. By contrast, downregulated expression of the
uPAR was associated with decreased tumor cell invasion and
metastasis.Available online http://breast-cancer-research.com/content/9/6/R76
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MMP activity is tightly regulated by specific physiological
inhibitors, TIMPs [29]. The TIMP family comprises at least four
distinct members: TIMP-1, TIMP-2, TIMP-3 and TIMP-4. Ets-1
is a member of the Ets family of transcription factors. It has
been reported that Ets-1 was overexpressed in a variety of
human malignancies, including breast cancers [30]. Because
of its roles in the transcriptional regulation of MMPs, Ets-1 is a
candidate mediator of cancer invasion and metastasis. In the
present study, we demonstrated that the enhancement of inva-
sive phenotype of breast cancer cells by PRDX6 was accom-
panied by upregulation of MMP-9 and Ets-1 expression and
downregulation of TIMP-2 expression. However, no significant
differences in expression of other members of the MMP and
TIMP families were found among PRDX6-transfected, knock-
down and parental cells. This suggested that the upregulation
of MMP-9 might be stimulated by PRDX6 through activation of
Ets-1 and deactivation of TIMP-2.
RhoC is a member of the Ras-homology family of small
GTP(guanosine triphosphate)-binding proteins. Some studies
have proved that RhoC had a key role in metastasis of breast
cancer [31]. In this study, our results suggested that the effect
of PRDX6 on the invasive and metastatic potential of breast
cancer cells was mediated partially through regulation of
RhoC expression.
In this study, we also demonstrated that PRDX6 enhanced
orthotopic tumor growth and pulmonary metastasis in nude
mice. By contrast, PRDX6 knockdown cells showed
decreased ability in breast cancer growth, invasiveness, and
metastasis. These changes were associated with regulation of
MMP-9, Est-1, the uPAR, Rhoc and TIMP-2 proteins in
xenograft tumors. All these results indicate that PRDX6 pro-
motes breast cancer progression, partially through
upregulation of uPAR, Ets-1, MMP-9 and RhoC expression
and downregulation of TIMP-2 expression.
Conclusion
We identified upregulation of PRDX6 in highly invasive and
potentially metastatic MDA-MB-231HM breast cancer cells
compared with their parental cells. Furthermore, we demon-
strated that overexpression of PRDX6 in breast cancer cells
promoted their invasive and metastatic potential in vitro and in
vivo. Conversely, experimental inhibition of PRDX6 expression
decreased the invasive and potential potential of breast can-
cer cells, partially through regulation of uPAR, Ets-1, MMP-9,
RhoC and TIMP-2 expression. These results are consistent
with our previous hypothesis that PRDX6 expression contrib-
utes to cellular invasive and metastatic potential.
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